Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
- Conditions
- Recurrent Childhood Supratentorial Primitive Neuroectodermal TumorEwing Sarcoma of BoneMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorAdult Supratentorial Primitive Neuroectodermal Tumor (PNET)Extraosseous Ewing SarcomaUntreated Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Interventions
- Drug: etoposideDrug: ifosfamideRadiation: intensity-modulated radiation therapyDrug: topotecan hydrochlorideDrug: busulfanDrug: melphalanProcedure: autologous hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationProcedure: autologous bone marrow transplantation
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT01795430
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Azienda Ospedaliera San Giovanni Battista
- Target Recruit Count
- 42
- Registration Number
- NCT01786018
- Locations
- 🇮🇹
Città della Salute e della Scienza di Torino, Torino, Italy
GVAX vs. Placebo for MDS/AML After Allo HSCT
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 123
- Registration Number
- NCT01773395
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214Recurrent Adult Acute Myeloid LeukemiaAcute Myeloid Leukemia With Gene MutationsAcute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOMChronic Lymphocytic LeukemiaTherapy-Related Acute Myeloid LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveHodgkin LymphomaMyelodysplastic Syndrome
- Interventions
- Drug: Fludarabine phosphateDrug: BusulfanRadiation: Total-Body IrradiationBiological: Therapeutic Allogeneic LymphocytesDrug: CyclophosphamideProcedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Peripheral Blood Stem Cell TransplantationDrug: TacrolimusDrug: Mycophenolate MofetilOther: Laboratory Biomarker Analysis
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2023-01-06
- Target Recruit Count
- 62
- Registration Number
- NCT01760655
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT01758328
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation
- Conditions
- Interventions
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 3
- Registration Number
- NCT01749293
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT01746173
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection
- Conditions
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Calimmune, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT01734850
- Locations
- 🇺🇸
UCLA CARE Center, Los Angeles, California, United States
🇺🇸Quest Clinical Research, San Francisco, California, United States
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)de Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 20
- Registration Number
- NCT01707004
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- St. Anna Kinderkrebsforschung
- Target Recruit Count
- 3300
- Registration Number
- NCT01704716
- Locations
- 🇵🇱
Medical University in Gdansk, Gdansk, Poland
🇵🇱Children's University Hospital in Lublin, Lublin, Poland
🇵🇱University of Medical Sciences Poznan, Poznan, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.